Source comparison
Thymosin Alpha-1 Bioavailability: Route Comparison
Subcutaneous Injection 80–90% 2–4 hours ~2 hours Direct absorption into capillaries; bypasses first-pass metabolism Gold standard for therapeutic use. Only route with clinical efficacy data Oral (Standard Formulation) <3% N/A (insufficient absorption) N/A Gast
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- 80–90%
- 2–4 hours
- ~2 hours
- Direct absorption into capillaries; bypasses first-pass metabolism
- Gold standard for therapeutic use. Only route with clinical efficacy data
- Oral (Standard Formulation)
- <3%
- N/A (insufficient absorption)
- N/A
- Gastric acid hydrolysis, pepsin cleavage, hepatic metabolism
- Pharmacologically ineffective. Negligible systemic exposure
- Intravenous (Rarely Used)
- ~95%
- Immediate
- Instant systemic circulation; no absorption phase
- Higher bioavailability but no clinical advantage over subcutaneous; impractical for routine use
- Intranasal (Experimental)
- 15–25%
- 30–60 minutes
- ~1.5 hours
- Mucosal absorption bypasses GI tract; still subject to nasal peptidases
- Experimental only. Not FDA-approved; limited stability data
- This table uses data from pharmacokinetic studies published in Journal of Immunotherapy and Clinical Pharmacokinetics. The subcutaneous route remains the only administration method with peer-reviewed efficacy evidence in human trials. Intranasal formulations show higher bioavailability than oral but remain far below subcutaneous absorption and lack long-term stability data.